DiagnoCure announces the completion of the $25,155,000 public offering


    Ticker Symbol: CUR

    QUEBEC CITY, April 3 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR)
("DiagnoCure") is pleased to announce the completion of a public offering of
5,850,000 common shares at a price of $4.30 per share, for gross proceeds of
    This offering was conducted through a syndicate of underwriters led by
National Bank Financial Inc. and including Orion Securities Inc., Canaccord
Capital Corporation and Industrial Alliance Securities Inc. for the offering
of the common shares. DiagnoCure has granted the underwriters an
over-allotment option to acquire an additional 877,500 common shares at a
price of $4.30 per share, which may be exercised during the next 30-day
    The Company intends to use the net proceeds of this offering to support
the implementation of its business plan, namely to expand the product
portfolio and acquire or in-license additional cancer diagnostic products.

    The securities offered have not been registered under the United States
    securities act of 1933, as amended, and may not be offered or sold within
    the United States absent registration or an exemption from the
    registration requirements thereunder. This release does not constitute an
    offer to sell or the solicitation of an offer to buy nor shall there be
    any sale of the securities in any state in which such offer, solicitation
    or sale would be unlawful.

    About DiagnoCure

    DiagnoCure specializes in the development, production and
commercialization of molecular diagnostics for the detection and management of
cancer. Its first test, ImmunoCyt(TM) / uCyt+(TM) for bladder cancer, is
distributed worldwide. In 2003, the Company entered into a strategic alliance
with Gen-Probe (NASDAQ:   GPRO) for the development and commercialization of a
second generation PCA3-based diagnostic test for prostate cancer. This test is
now available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) as well as in Europe as the CE-marked Gen-Probe PROGENSA(TM)
PCA3 in vitro assay. The Company plans to expand its product portfolio, namely
in prostate, lung and other cancers. In addition to its own research, the
Company intends to acquire or in-license promising cancer biomarkers from both
academic and commercial institutions. Additional information can be found at

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects and future revenues are based on
management expectations. In addition, the reader is referred to the applicable
general risks and uncertainties described in DiagnoCure's most recent Annual
Information Form under the heading "Risk Factors". DiagnoCure undertakes no
obligation to publicly update or revise any forward-looking statements
contained herein.
    %SEDAR: 00003671EF

For further information:

For further information: Thom Skinner, Chief Financial Officer,
DiagnoCure Inc., (418) 527-6100, communications@diagnocure.com

Organization Profile

DiagnoCure Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890